Gain Therapeutics, Inc.GANXNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +108.89% | +67.42% | +59.55% | +57.90% | +31.91% |
| Weighted Average Shares Diluted Growth | +108.89% | +67.42% | +59.55% | +57.90% | +31.91% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +266.72% | +215.68% | -100.00% | -100.00% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +1.90% | -34.85% | -20.26% | -48.77% | -23.63% |
| Book Value per Share Growth | -41.82% | -65.15% | -58.08% | -80.14% | -49.72% |
| Debt Growth | -25.94% | -36.44% | -31.78% | -15.72% | -76.48% |
| R&D Expense Growth | +16.76% | -48.64% | -10.63% | -28.62% | -3.40% |
| SG&A Expenses Growth | -27.02% | +3.79% | +12.70% | -37.28% | +4.69% |